<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045443</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU MD 134/2021</org_study_id>
    <nct_id>NCT05045443</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia</brief_title>
  <acronym>CurcumPedALL</acronym>
  <official_title>Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of of the biological effects of curcumin on microbiota in children with acute&#xD;
      lymphoblastic leukemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the safety of curcumin, which is the most active constituent of the ground&#xD;
      rhizome of the Curcuma longa plant, in children with acute lymphoblastic leukemia patients&#xD;
      (ALL) in maintenance phase of chemotherapy through the assessment of the any reported adverse&#xD;
      event (AE). And assessment of the curcumin effect on health by eliminating intestinal&#xD;
      microflora dysbiosis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Safety of curcumin in pediatric patients with ALL.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of patients who developed adverse event</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Lymphoblastic Leukemia, Pediatric</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement (composed of Tumeric (curcuma longa)root 450mg and Tumeric extract (curcuma longa )root 50mg ) standardized to contain 95%curcuminoids, it will given twice daily for 1 month starting at week 1 of maintenance phase of chemotherapy (Time 1) . It is preferably to be taken with meals but may be opened and prepared as a tea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of nutritional care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of nutritional support care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement</description>
    <arm_group_label>Curcumin</arm_group_label>
    <other_name>Tumeric curcumin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>As per institution protocol for Standard of nutritional Care</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Standard of nutritional care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Children aged from 1 year to 18 years Children with proven ALL diagnosed by bone marrow&#xD;
        aspirate and immunephenotyping Patients in the maintenance phase week1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Children with other maliganacies, Current use (past use of these medications is not an&#xD;
        exclusion) of medications or over-the-counter treatments including to sulfasalazine,&#xD;
        warfarin, clopidogrel, aspirin, antacids, botanical treatments (ginger, feverfew, yellow&#xD;
        clover, Salix species, Populus species, Betula species, and Gaultheria species), essential&#xD;
        fatty acids (flax oil and fish oil).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ihab Khairy, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatma S Ebeid, MD</last_name>
    <phone>+201095569596</phone>
    <email>dr.fatma_ebeid@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yasmin Gamal, MD</last_name>
    <email>yasmingamal@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pediatric Hematology Oncology and BMT Unit, Faculty of Medicine Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Non-US</state>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatma Soliman E Ebeid</last_name>
      <phone>01095569596</phone>
      <email>dr.fatma_ebeid@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Nihal Hussein</last_name>
      <email>nihal.hussien.ali@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Fatma Soliman Elsayed Ebeid</investigator_full_name>
    <investigator_title>Professor of pediatrics Hematology Oncology and Bone Marrow Transplant</investigator_title>
  </responsible_party>
  <keyword>Curcumin</keyword>
  <keyword>Ain Shams University</keyword>
  <keyword>Egypt</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

